Aradigm/Novo Nordisk Inhaled Insulin Manufacturing Issues Appear Resolved
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerns over cosmetic blemishes on liquid insulin strips had delayed initiation of additional Phase III trials. Aradigm sees increased interest in its AERx pulmonary delivery system in the wake of Pfizer’s recent optimism about Exubera.